The European Commission informed Teva on Monday 10 October of its preliminary view that the company had breached EU rules on anti-competitive behaviour by engaging in practices designed to delay competition for its medicine Copaxone.
These practices consisted of an artificial extension of the patent protection of Copaxone and the systematic dissemination of misleading information about a competing product in order to hinder its market entry and uptake.
Teva’s blockbuster medicine...